Document Detail


Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review.
MedLine Citation:
PMID:  22539192     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: This systematic review assesses the effectiveness of intravitreal bevacizumab (IVB) versus a comparison group in the treatment of branch retinal vein occlusion (BRVO)-associated macular edema, and explores its effects on visual acuity (VA) and central macular thickness (CMT).
METHODS: The authors searched the following databases: Medline (1950-October week 3, 2011), The Cochrane Library (Issue 10, 2011), EMBASE (up to 24 October 2011), and the TRIP Database (up to 24 October 2011), using no language or other limits. Trials that were included consisted of patients with BRVO-associated macular edema, those comparing a 1.25 mg IVB injection with a comparison group, those reporting both VA and CMT outcomes, and those having a minimum follow-up of 4 weeks.
RESULTS: In the four trials comparing IVB with a comparison group, IVB was effective in improving VA and CMT values in the long-term (12 weeks) in patients with BRVO-associated macular edema. Furthermore, statistically significant improvements in VA in the short-term (4 weeks) could also be seen.
DISCUSSION: Clinicians should use this review as an indicator that IVB is effective in improving VA and CMT values in the long-term in patients with BRVO-associated macular edema. It is important to note, however, that statistically significant improvements in VA in the short term could be seen. This review's main aim was to serve as an evidence base for potentially using other modalities, such as IVB, which seems to be reserved for certain cases.
Authors:
Taygan Yilmaz; Miguel Cordero-Coma
Publication Detail:
Type:  Journal Article; Review     Date:  2012-04-27
Journal Detail:
Title:  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie     Volume:  250     ISSN:  1435-702X     ISO Abbreviation:  Graefes Arch. Clin. Exp. Ophthalmol.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-21     Completed Date:  2012-07-31     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8205248     Medline TA:  Graefes Arch Clin Exp Ophthalmol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  787-93     Citation Subset:  IM    
Affiliation:
Harvard Vanguard Medical Associates, Department of Visual Services, 133 Brookline Avenue, Boston, MA 02215, USA. Taygan.yilmaz@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / administration & dosage,  therapeutic use*
Antibodies, Monoclonal, Humanized / administration & dosage,  therapeutic use*
Clinical Trials as Topic
Databases, Factual
Humans
Intravitreal Injections
Macular Edema / drug therapy*,  etiology,  physiopathology
Retina / pathology
Retinal Vein Occlusion / complications,  drug therapy*,  physiopathology
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab
Comments/Corrections
Comment In:
Graefes Arch Clin Exp Ophthalmol. 2012 Jul;250(7):955-6   [PMID:  22527322 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Negative emotional photographs are identified more slowly than positive photographs.
Next Document:  Changes in PACAP Immunoreactivity in Human Milk and Presence of PAC1 Receptor in Mammary Gland durin...